Tyrosine Kinase Inhibitors
DBCAT001447Pharmacologic class
Protein kinase inhibitors that inhibit TYROSINE PROTEIN KINASES. A DrugBank category of 94 drugs. 63 of them are approved.
- Also known as
- Protein Tyrosine Kinase Inhibitor · TKIs · Protein-Tyrosine Kinases, antagonists & inhibitors
- Drugs
- 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone
- Abivertinib
- Acalabrutinib
- Afatinib
- Alectinib
- Asciminib
- Avapritinib
- Axitinib
- Bosutinib
- Brepocitinib
- Brigatinib
- Cabozantinib
- Canertinib
- Capmatinib
- Cediranib
- Ceritinib
- Crenolanib
- Crizotinib
- Dacomitinib
- Dasatinib
- Deucravacitinib
- Dovitinib
- Entrectinib
- Erdafitinib
- Erlotinib
What you can answer from here — as of August 07, 2018
Which targets do Tyrosine Kinase Inhibitors share, and which companies have late-stage candidates in this class?
Create a free account or log in to explore the full data card.
Create Account